Lung cancer: Copayments and behavior following erlotinib formulary tier change

American Journal of Pharmacy Benefits

Volumn 4, Issue 6, 2012, Pages

  Engel Nitz, Nicole M ^a   Satram Hoang, Sacha ^b   Cao, Feng ^b   Reyes, Carolina M ^b  

^a OptumInsight   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; COHORT ANALYSIS; COMORBIDITY; DRUG COST; DRUG FORMULARY; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED STATES;

EID: 84869831990     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. American Cancer Society. What is non-small cell lung cancer. http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. Published 2011. Accessed Dec 21, 2011.
2. Brown ML, Riley G F, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8) (suppl):IV 104-117.
3. Page N, Read W, Tierney R, et al. The epidemiology of small cell lung carcinoma [abstract 1216]. Proc Am Soc Clin Oncol. 2002;21:305.
4. Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: factors infl uencing treatment selection. Oncologist. 2006;11(6):655-665.
5. Govindan R, Garfi eld DH. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol. 2004;31(6) (suppl 11):27-31.
6. Curtiss FR. Pharmacy benefi t spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12(7):570-577.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
8. Hede K. Increase in oral cancer drugs raises thorny issues for oncology practices. J Natl Cancer Inst. 2009;101(22):1534-1536.
9. Webb T. Under-dosing study raises questions about ways to improve regimen adherence. J Natl Cancer Inst. 2004;96(16):1201-1202.
10. Tsang J, Rudychev I, Pescatore S. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (Pts) on imatinib (IM): 2006 ASCP Annual Meeting Proceedings, part I. J Clin Oncol. 2006;24(18S)(suppl):6119.
11. Wu EQ, Guerin A, Yu A P, Bollu VK, Guo A, Griffi n JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasat-inib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26(12):2861-2869.
12. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmaco-economics. 2007;25(6):481-496.
13. Zivin K, Ratliff S, Heisler MM, Langa KM, Piette JD. Factors infl uencing cost-related nonadherence to medication in older adults: a conceptually based approach. Value Health. 2010;13(4):338-345.
14. Piette JD, Heisler M, Horne R, Caleb Alexander G. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. Soc Sci Med. 2006;62(4):846-857.
15. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125(1):191-200.
16. Moore S. Nonadherence in patients with breast cancer receiving oral therapies. Clin J Oncol Nurs. 2010;14(1):41-47.
17. St. Charles M, Bollu VK, Hornyak E, Coombs J, Blanchette CM, DeAngelo D. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. ASH Annual Meeting Abstracts. 2009 114:2209.
18. Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26(1):61-69.
19. Greer JA, Pirl W F, Park ER, Lynch TJ, Temel JS. Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. J Psychosom Res. 2008;65(6):549-552.
20. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care. 2008;14(5):297-306.
21. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449-457.
22. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574.
23. Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7(3)(suppl):46s-51s.
24. Timmers L, Boons CC, Mangnus D, et al. The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer. 2011;11:284.
25. Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract. 2011;7(1): 65-67.
26. Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66(2):85-96.
27. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):523-526.
28. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4): 602-606.
29. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832-839.
30. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19(2):322-328.
31. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;109(5):832-839.
32. Madden JM, Graves AJ, Ross-Degnan D, Briesacher BA, Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. JAMA. 2009;302(16):1755-1756.
33. Weingart SN, Spencer J, Bula D, et al. Medication safety of fi ve oral chemotherapies: a proactive risk assessment. J Oncol Pract. 2011;7(1):2-6.
34. Cohen MH, Johnson JR, Chattopadhyat S, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010;15(3):1344-1351. E3